SG2918 For Advanced Malignant Tumors

Advanced Malignant Tumors Clinical Trial

Official title:

A Phase I Clinical Study to Evaluate the Safety Tolerability and Preliminary Efficacy of SG2918 in Subjects With Advanced Malignant Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06167486
• Other study ID #: CSG-2918-101
• Status: Recruiting
• Phase: Phase 1
• Start date: December 26, 2023
• Est. completion date: December 28, 2026

Study information

• Verified date: November 2023
• Source: Hangzhou Sumgen Biotech Co., Ltd.
• Contact: Zhengbo Song, Docter
• Phone: 86-13857153345
• Email: songzb[@]zjcc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 in subjects with Advanced Malignant Tumors who are refractory or resistant to standard therapy, or without available standard or curative therapy.

Description:

The study consists of dose escalation and dose expansion, the dose escalation will be performed in a standard 3+3 manner at the dose of 0.1mg/kg、0.5mg/kg、1 mg/kg、1.5mg/kg、2 mg/kg、2.5mg/kg and 3 mg/kg, and the dose expansion will be done in specific tumor types. Patients enrolled in the study will receive SG2918 treatment every three weeks (Q3W), until disease progression, intolerable toxicity or others, whichever occurs first.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 117
• Est. completion date: December 28, 2026
• Est. primary completion date: December 28, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Histologically or cytologically documented advanced malignant tumors that is refractory/relapsed to standard therapies;

2. Adequate organ function;

3. ECOG Performance Status score of 0 or 1;

4. Must have at least one measurable lesion according to RECIST Version1.1;

5. Toxicity caused by prior anti-tumor therapy recovered to Grade 0 to 1 (CTCAE 5.0);

6. Must have an effective contraception during the study, starting with the Screening Visit through 7 months after the last dose of study intervention.

Exclusion Criteria:

1. Has active central nervous system metastatic lesions;

2. Has Active autoimmune disease requiring systemic therapy within the past 2 years;

3. Has Grade 2 and above peripheral neuropathy;

4. Has an active infection requiring systemic therapy;

5. Has a history of any of the following cardiovascular conditions within 6 months of dosing: myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, coronary artery bypass graft, pulmonary embolism, etc; has New York Heart Association (NYHA) Class II and above congestive heart failure; LVEF<50%;

6. Has a history of hypertensive crisis or hypertensive encephalopathy; Uncontrolled hypertension though standard treatment within 14 days before the first dose (systolic blood pressure=160 mmHg and/or diastolic blood pressure=100mmHg);

7. Has known human immunodeficiency virus (HIV) and/or hepatitis B or C infections;

8. Has a history of potent CYP3A4 inhibitor with 2 weeks;

9. Has received systemic anticancer therapy, radiotherapy, or surgery within 4 weeks before the start of study treatment;

10. Have received previous treatment targeted LILRB4 or MMAE experiencing serious adverse events;

11. Have received previous immunotherapy experiencing serious adverse events that leading to permanent discontinuation;

12. Have received systemic corticosteroids (equivalent dose > 10 mg/day of prednisone) or other immunosuppressive drugs within 14 days prior to the first dose;

13. Has had a severe hypersensitivity reaction to treatment with a monoclonal antibody (mAB) and or any components of the study intervention;

14. Any live vaccine within 28 days prior to the first dose;

15. Has a history of interstitial lung disease or active pneumonia or tracheal fistula; uncontrolled pleural, abdominal and pericardial effusion;

16. Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 year.

Related Conditions & MeSH terms

• Advanced Malignant Tumors
• Neoplasms

Intervention

Drug:
• SG2918
The SG2918 will be administrated by intravenous infusion every 3 weeks

Locations

Country	Name	City	State
China	Hunan Cancer Hospital	Changsha	Hunan
China	Chongqing University Cancer Hospital	Chongqing	Chongqing
China	Zhejiang Cancer Hospital	Hangzhou	Zhejiang
China	Shanghai first maternity and infant hospital	Shanghai	Shanghai
China	Shanxi Provincial Cancer Hospital	Taiyuan	Shanxi
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Hangzhou Sumgen Biotech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events	Number and percentage of AEs which is calculated by worst CTCAE grade by CTCAE 5.0	From the time of first dose until 30 days after last dose of SG2918
Primary	Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)	DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria and assessed as related to study drug, and unrelated to disease, disease progression, intercurrent illness or concomitant medications that occurs within the first cycle (three weeks) of treatment.	Cycle 1 (up to 21 days)
Secondary	Pharmacokinetics(PK): Cmax	Maximum drug concentration after administration	From the time of first dose until 30 days after last dose of SG2918
Secondary	Pharmacokinetics (PK): AUC	Area Under the Curve of the drug after administration	From the time of first dose until 30 days after last dose of SG2918
Secondary	Pharmacokinetics (PK): T1/2	Elimination half-life of the drug after administration	From the time of first dose until 30 days after last dose of SG2918
Secondary	Pharmacokinetics (PK): CL	Clearance of the drug after administration	From the time of first dose until 30 days after last dose of SG2918
Secondary	Pharmacodynamic(PD): cellular biomarkers	cellular biomarkers including CD4+ T cells, CD8+ T cells, Myeloid-derived suppressor cells (MDSCs) and Regulatory T cells (Tregs)	From the time of first dose until 30 days after last dose of SG2918
Secondary	Pharmacodynamic(PD): cytokine levels	Peripheral blood cytokine levels including measurements for TNF-a,IFN-?,IL-2,IL-4?IL-6,IL-8,IL-10,IL-1ß	From the time of first dose until 30 days after last dose of SG2918
Secondary	Immunogenicity endpoints	Levels of anti-drug antibodies(ADAs) and neutralizing antibodies (tested in ADA-positive samples)	Through study completion, an average of one year,assessed up to approximately 12 months
Secondary	Efficacy endpoints	objective response rate (ORR)	Through study completion, an average of one year,assessed up to approximately 12 months